Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Blood group B antigen is a complex carbohydrate structure expressed on the surface of erythrocytes, endothelial cells, and epithelial cells in individuals with blood type B or AB (StatPearls, NBK554381). It is synthesized by the action of the ABO glycosyltransferase, specifically the B transferase, which attaches an alpha-1,3-linked galactose residue to the H antigen precursor (UniProt, P12432). In clinical medicine, the B antigen is a primary barrier to safe blood transfusion and organ transplantation because individuals with type A or O blood produce pre-existing IgM antibodies against it. These anti-B antibodies can cause rapid, life-threatening intravascular hemolysis if B-positive blood is administered to an incompatible recipient. Research into the B antigen includes the use of specific alpha-galactosidase enzymes to strip the terminal galactose, effectively converting B-type blood into universal O-type blood (Nature Microbiology, s41564-019-0469-7). Additionally, the expression of B antigens on non-erythroid tissues influences susceptibility to various pathogens and the risk of developing certain cardiovascular and oncological conditions (PubMed, 32107131). Management of this target is essential in desensitization protocols for ABO-incompatible organ transplants using therapies like Rituximab and plasmapheresis.
Antibody-mediated agglutination and hemolysis; enzymatic cleavage of the terminal alpha-1,3-galactose residue to convert B antigen to H antigen (Type O).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Blood group B antigen (B antigen).